Y. Gu

893 total citations
15 papers, 598 citations indexed

About

Y. Gu is a scholar working on Dermatology, Immunology and Surgery. According to data from OpenAlex, Y. Gu has authored 15 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Dermatology, 7 papers in Immunology and 5 papers in Surgery. Recurrent topics in Y. Gu's work include Psoriasis: Treatment and Pathogenesis (7 papers), Colorectal and Anal Carcinomas (5 papers) and Hidradenitis Suppurativa and Treatments (5 papers). Y. Gu is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (7 papers), Colorectal and Anal Carcinomas (5 papers) and Hidradenitis Suppurativa and Treatments (5 papers). Y. Gu collaborates with scholars based in United States, Canada and Denmark. Y. Gu's co-authors include Alexa B. Kimball, Gregor B. E. Jemec, M Sundaram, Martin M. Okun, Henrique D. Teixeira, David Williams, Parvez Mulani, Jeffrey M. Sobell, Christos C. Zouboulis and James Signorovitch and has published in prestigious journals such as Diabetes, Journal of Investigative Dermatology and British Journal of Dermatology.

In The Last Decade

Y. Gu

14 papers receiving 592 citations

Peers

Y. Gu
Rosa Fernández‐Torres Spain
Richuan Zheng Japan
Martin Schlaeger Germany
Natalia Rompoti Greece
Jeff Simpson United Kingdom
Hajnalka Jókai Hungary
Lisa Eisert Germany
Shireen Sidhu Australia
R.J.G. Chalmers United Kingdom
Kara Creamer United States
Rosa Fernández‐Torres Spain
Y. Gu
Citations per year, relative to Y. Gu Y. Gu (= 1×) peers Rosa Fernández‐Torres

Countries citing papers authored by Y. Gu

Since Specialization
Citations

This map shows the geographic impact of Y. Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y. Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y. Gu more than expected).

Fields of papers citing papers by Y. Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Y. Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y. Gu. The network helps show where Y. Gu may publish in the future.

Co-authorship network of co-authors of Y. Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Y. Gu. A scholar is included among the top collaborators of Y. Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Y. Gu. Y. Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
3.
Jemec, Gregor B. E., Martin M. Okun, Seth Forman, et al.. (2019). Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. British Journal of Dermatology. 181(5). 967–975. 41 indexed citations
4.
Gniadecki, Robert, C. Leonardi, Kenneth B. Gordon, et al.. (2018). Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology. 32(8). 1297–1304. 7 indexed citations
5.
Shi, Hongyu, Yini Li, & Y. Gu. (2018). Effects of a micro-derived antioxidant on semen parameters of males with asthenozoospermia. New Biotechnology. 44. S31–S31. 2 indexed citations
6.
Gulliver, Wayne, Martin M. Okun, Antonio Martorell, et al.. (2016). 006 Therapeutic response guided dosing strategy to optimize long-term adalimumab treatment in patients with hidradenitis suppurativa: integrated results from the PIONEER phase 3 trials. Journal of Investigative Dermatology. 136(9). S161–S161. 4 indexed citations
7.
Cai, Lin, Jie Zheng, Min Zheng, et al.. (2016). Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study. Journal of the European Academy of Dermatology and Venereology. 31(1). 89–95. 79 indexed citations
8.
Kimball, Alexa B., Jeffrey M. Sobell, Christos C. Zouboulis, et al.. (2015). HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo‐controlled portion of a phase 2 adalimumab study. Journal of the European Academy of Dermatology and Venereology. 30(6). 989–994. 143 indexed citations
9.
Kimball, Alexa B., Gregor B. E. Jemec, Min Yang, et al.. (2014). Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. British Journal of Dermatology. 171(6). 1434–1442. 142 indexed citations
10.
Papp, Kim, M Sundaram, Yanjun Bao, et al.. (2013). Effects of briakinumab treatment for moderate to severe psoriasis on health‐related quality of life and work productivity and activity impairment: results from a randomized phase III study. Journal of the European Academy of Dermatology and Venereology. 28(6). 790–798. 21 indexed citations
11.
Mrowietz, Ulrich, Knud Kragballe, Kristian Reich, et al.. (2012). An assessment of adalimumab efficacy in three Phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. British Journal of Dermatology. 168(2). 374–380. 15 indexed citations
12.
Papp, Kim, Alan Menter, Yves Poulin, Y. Gu, & Eric H. Sasso. (2012). Long‐term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open‐label extension study. Journal of the European Academy of Dermatology and Venereology. 27(5). 634–642. 43 indexed citations
13.
Leonardi, C., Jeffrey M. Sobell, Jeffrey Crowley, et al.. (2012). Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. British Journal of Dermatology. 167(3). 658–667. 34 indexed citations
14.
Kimball, Alexa B., Francisco A. Kerdel, David R. Adams, et al.. (2012). Adalimumab for the treatment of moderate to severe hidradenitis suppurativa:A parallel randomized trial. Research at the University of Copenhagen (University of Copenhagen). 36 indexed citations
15.
Langley, Richard G., Bruce Strober, Y. Gu, Stephen J. Rozzo, & Martin M. Okun. (2010). Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis. British Journal of Dermatology. 162(6). 1349–1358. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rosa Fernández‐Torres Breakdown of academic impact, for papers by Richuan Zheng Breakdown of academic impact, for papers by Martin Schlaeger Breakdown of academic impact, for papers by Natalia Rompoti Breakdown of academic impact, for papers by Jeff Simpson Breakdown of academic impact, for papers by Hajnalka Jókai Breakdown of academic impact, for papers by Lisa Eisert Breakdown of academic impact, for papers by Shireen Sidhu Breakdown of academic impact, for papers by R.J.G. Chalmers Breakdown of academic impact, for papers by Kara Creamer
Rankless by CCL
2026